OBJECTIVE: To investigate whether phosphorylated tau protein (tau-pT181) is increased in variant Creutzfeldt-Jakob disease (vCJD) and if the tau-pT181/tau protein ratio is useful for distinguishing between patients with and without CJD. METHODS: CSF tau protein and tau-pT181 were measured in 50 patients with sporadic CJD (sCJD), 51 patients with vCJD, 46 sCJD controls, and 37 vCJD controls, using Innotest hTau and Innotest P-Thr181, Innogenetics. RESULTS: Concentrations of CSF tau protein were increased in sCJD (5120 v 367 pg/ml in controls, p < 0.001) and vCJD (952 v 106 pg/ml, p < 0.001); tau-pT181 was also raised in sCJD (61 v 35 pg/ml in controls, p = 0.002) and vCJD (114 v 33 pg/ml, p < 0.001). Median concentrations of tau-pT181 were higher in vCJD than in sCJD (p < 0.001). The tau-pT181/tau protein ratio was lower than in controls in both sCJD (12 v 128 (p < 0.001)) and vCJD (119 v 279 (p < 0.001)). Mean tau-pT181/tau protein ratio was 10-fold higher in vCJD than in sCJD. Raised CSF tau protein had the highest efficiency for distinguishing sCJD and vCJD from controls. CONCLUSIONS: CSF tau-pT181 concentrations are raised in vCJD and are higher than in sCJD. Measurement of CSF tau-pT181/tau protein ratio does not improve the diagnostic efficiency of CSF tau protein alone for either vCJD or sCJD. The higher concentration of CSF tau-pT181 found in vCJD suggests that unexplained pathogenic factors influence the phosphorylation of tau protein in vCJD patients.
OBJECTIVE: To investigate whether phosphorylated tau protein (tau-pT181) is increased in variant Creutzfeldt-Jakob disease (vCJD) and if the tau-pT181/tau protein ratio is useful for distinguishing between patients with and without CJD. METHODS: CSF tau protein and tau-pT181 were measured in 50 patients with sporadic CJD (sCJD), 51 patients with vCJD, 46 sCJD controls, and 37 vCJD controls, using Innotest hTau and Innotest P-Thr181, Innogenetics. RESULTS: Concentrations of CSF tau protein were increased in sCJD (5120 v 367 pg/ml in controls, p < 0.001) and vCJD (952 v 106 pg/ml, p < 0.001); tau-pT181 was also raised in sCJD (61 v 35 pg/ml in controls, p = 0.002) and vCJD (114 v 33 pg/ml, p < 0.001). Median concentrations of tau-pT181 were higher in vCJD than in sCJD (p < 0.001). The tau-pT181/tau protein ratio was lower than in controls in both sCJD (12 v 128 (p < 0.001)) and vCJD (119 v 279 (p < 0.001)). Mean tau-pT181/tau protein ratio was 10-fold higher in vCJD than in sCJD. Raised CSF tau protein had the highest efficiency for distinguishing sCJD and vCJD from controls. CONCLUSIONS: CSF tau-pT181 concentrations are raised in vCJD and are higher than in sCJD. Measurement of CSF tau-pT181/tau protein ratio does not improve the diagnostic efficiency of CSF tau protein alone for either vCJD or sCJD. The higher concentration of CSF tau-pT181 found in vCJD suggests that unexplained pathogenic factors influence the phosphorylation of tau protein in vCJD patients.
Authors: R G Will; M Zeidler; G E Stewart; M A Macleod; J W Ironside; S N Cousens; J Mackenzie; K Estibeiro; A J Green; R S Knight Journal: Ann Neurol Date: 2000-05 Impact factor: 10.422
Authors: M Otto; J Wiltfang; H Tumani; I Zerr; M Lantsch; J Kornhuber; T Weber; H A Kretzschmar; S Poser Journal: Neurosci Lett Date: 1997-04-11 Impact factor: 3.046
Authors: E Kapaki; K Kilidireas; G P Paraskevas; M Michalopoulou; E Patsouris Journal: J Neurol Neurosurg Psychiatry Date: 2001-09 Impact factor: 10.154
Authors: M Riemenschneider; S Wagenpfeil; H Vanderstichele; M Otto; J Wiltfang; H Kretzschmar; E Vanmechelen; H Förstl; A Kurz Journal: Mol Psychiatry Date: 2003-03 Impact factor: 15.992
Authors: R G Will; A Alperovitch; S Poser; M Pocchiari; A Hofman; E Mitrova; R de Silva; M D'Alessandro; N Delasnerie-Laupretre; I Zerr; C van Duijn Journal: Ann Neurol Date: 1998-06 Impact factor: 10.422
Authors: B Van Everbroeck; A J E Green; E Vanmechelen; H Vanderstichele; P Pals; R Sanchez-Valle; N Cuadrado Corrales; J-J Martin; P Cras Journal: J Neurol Neurosurg Psychiatry Date: 2002-07 Impact factor: 10.154
Authors: P Piccardo; J Cervenak; O Yakovleva; L Gregori; K Pomeroy; A Cook; F S Muhammad; T Seuberlich; L Cervenakova; D M Asher Journal: J Comp Pathol Date: 2011-10-20 Impact factor: 1.311
Authors: Pascual Sánchez-Juan; Matthew T Bishop; Alison Green; Claudia Giannattasio; Alejandro Arias-Vasquez; Anna Poleggi; Richard S G Knight; Cornelia M van Duijn Journal: BMC Med Genet Date: 2007-12-11 Impact factor: 2.103